Gifu, Japan

Hiroaki Ushikoshi



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroaki Ushikoshi: Innovator in Heart Disease Treatment

Introduction

Hiroaki Ushikoshi is a notable inventor based in Gifu, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of heart diseases. His innovative approach focuses on gene therapy, which has the potential to revolutionize how heart conditions are treated.

Latest Patents

Ushikoshi holds a patent for a drug designed to prevent or treat heart diseases, which comprises an expression vector containing the CD9 gene as the active ingredient. This invention addresses various heart diseases, including heart failure, ischemic heart diseases, cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases, myocarditis, arrhythmia, and conditions associated with cardiac hypertrophy and/or tachycardia. The expression vector utilized in this invention can be either a viral vector or a non-viral vector. The method involves expressing the CD9 gene in the heart through gene therapy, which transfers the CD9 gene as a means of prevention or treatment.

Career Highlights

Ushikoshi is affiliated with the Nagoya Industrial Science Research Institute, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving health outcomes for patients suffering from heart diseases.

Collaborations

Ushikoshi collaborates with Kenichiro Kosai, a fellow researcher, to further enhance the impact of their work in the field of heart disease treatment.

Conclusion

Hiroaki Ushikoshi's innovative contributions to gene therapy for heart diseases highlight the potential for new treatment options in this critical area of healthcare. His work exemplifies the intersection of science and medicine, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…